Acting on its authorization to acquire up to 10% of its shares the H. Lundbeck Supervisory Board has resolved to initiate a share buyback program. Under the program H. Lundbeck will buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 on 17th August 2005. During any one single trading day a maximum of 25% of the average daily trading volume of Lundbeck shares on the Copenhagen Stock Exchange, calculated over 20 days prior to each trading date, will be bought back, as the share buyback program is implemented in accordance with the provisions of the European Commission's regulation no. 2273/2003 of December 22, 2003. At least once every seven trading days, Lundbeck will issue an announcement in respect of the transactions made under the program. The following transactions have been made under the program: No. of shares Average Transaction value purchase price (DKK) (DKK) Accumulated, last 21,191,621 135.1031 2,863,054,619 announcement 3 August 2007 4.029 141,1519 568.701,10 6 August 2007 107.916 138,9107 14.990.690,88 7 August 2007 108.933 137,1711 14.942.456,11 8 August 2007 83.148 133,8853 11.132.296,96 9 August 2007 112.522 131,6106 14.809.093,27 10 August 2007 125.804 128,1538 16.122.255,32 13 August 2007 -- -- -- Accumulated under the 21.733.973 135,1108 2.935.620.113 program Following the above buyback it is hereby announced that Lundbeck owns a total of 2,451,382 own shares at a nominal value of DKK 5, equal to 1.19% of the total number of 206,870,629 shares. The content of this release will have no influence on the Lundbeck Group's financial result for 2007. Lundbeck contacts Investors: Media: Jacob Tolstrup Caroline Broge Investor Relations Manager, Media Relations Manager North America +45 36 43 26 38 +1 201 350 0187 ________________________ Stock Exchange Release No 283 - 13 August 2007 About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com